Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sevabertinib - Bayer

Next Previous
Drug Profile

Sevabertinib - Bayer

Alternative Names: BAY-2927088

Latest Information Update: 09 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer; Broad Institute; Harvard University
  • Developer Bayer
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Non-small cell lung cancer
  • Phase II Solid tumours

Most Recent Events

  • 24 Jul 2025 Bayer initiates phase-I pharmacokinetics trial in USA (PO, Tablet) (NCT07102095)
  • 30 May 2025 Updated efficacy and adverse events data from a phase I/II trial in Non-small cell lung cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 28 May 2025 Preregistration for Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top